Neurocrine Biosciences, Inc. NBIX

NAS: NBIX | ISIN: US64125C1099   11/09/2026
156,22 USD (-0,22%)
(-0,22%)   11/09/2026

2 september 2026 · Neurocrine Biosciences to Present at Upcoming Investor Conferences in September · Persbericht

12 augustus 2026 · Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia · Persbericht

7 augustus 2026 · Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist · Persbericht

30 juli 2026 · Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results · Persbericht

23 juli 2026 · Neurocrine Biosciences Announces Key Leadership Hiring, Promotions · Persbericht

21 juli 2026 · Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer · Persbericht

9 juli 2026 · Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results · Persbericht

1 juli 2026 · Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia · Persbericht

15 juni 2026 · Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period · Persbericht

15 juni 2026 · Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026 · Persbericht

15 juni 2026 · Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026 · Persbericht

15 juni 2026 · Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026 · Persbericht

8 juni 2026 · Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients · Persbericht

8 juni 2026 · Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities · Persbericht

3 juni 2026 · Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026 · Persbericht

26 mei 2026 · Neurocrine Biosciences to Present at Upcoming Investor Conferences in June · Persbericht

18 mei 2026 · Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules · Persbericht

18 mei 2026 · Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics · Persbericht

6 mei 2026 · Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia · Persbericht

5 mei 2026 · Neurocrine Biosciences Reports First-Quarter 2026 Financial Results · Persbericht

Mijn selecties